A single nucleotide polymorphism in the Mdm2 promoter and risk of sepsis

American Journal of Surgery

Volumn 197, Issue 1, 2009, Pages 43-48

  Kleiman, David A ^a   Calvano, Jacqueline E ^a   Coyle, Susette M ^a   Macor, Marie A ^a   Calvano, Steve E ^a   Lowry, Stephen F ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Critical care; Genetic polymorphisms; Inflammation; Mdm2; Sepsis syndrome; SNP309

Indexed keywords

PROTEIN MDM2;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SEPSIS;

EID: 57649148564     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.12.049     Document Type: Article

References (38)

1. Villar J., Maca-Meyer N., Perez-Mendez L., et al. Bench-to-bedside review: understanding genetic predisposition to sepsis. Crit Care 8 (2004) 180-189
2. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003) 1250-1256
3. Holmes C.L., Russell J.A., and Walley K.R. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 124 (2003) 1103-1115
4. Arcaroli J., Fessler M.B., and Abraham E. Genetic polymorphisms and sepsis. Shock 24 (2005) 300-312
5. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 6 (2005) 1191-1197
6. Yamanishi Y., Boyle D.L., Pinkoski M.J., et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 160 (2002) 123-130
7. Hotchkiss R.S., Tinsley K.W., Hui J.J., et al. p53-dependent and -independent pathways of apoptotic cell death in sepsis. J Immunol 164 (2000) 3675-3680
8. Cheng T., Liu D., Griffin J.H., et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9 (2003) 338-342
9. Simelyte E., Rosengren S., Boyle D.L., et al. Regulation of arthritis by p53: critical role of adaptive immunity. Arthritis Rheum 52 (2005) 1876-1884
10. Power C.P., Wang J.H., Manning B., et al. Bacterial lipoprotein delays apoptosis in human neutrophils through inhibition of caspase-3 activity: regulatory roles for CD14 and TLR-2. J Immunol 173 (2004) 5229-5237
11. Hotchkiss R.S., Coopersmith C.M., and Karl I.E. Prevention of lymphocyte apoptosis-a potential treatment of sepsis?. Clin Infect Dis 41 suppl 7 (2005) S465-S469
12. Momand J., Wu H.H., and Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242 (2000) 15-29
13. Iwakuma T., and Lozano G. MDM2, an introduction. Mol Cancer Res 1 (2003) 993-1000
14. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
15. Arva N.C., Gopen T.R., Talbott K.E., et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280 (2005) 26776-26787
16. Moll U.M., and Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 1 (2003) 1001-1008
17. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (1996) 707-710
18. Salvo I., de Cian W., Musicco M., et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21 suppl. 2 (1995) S244-S249
19. Brown P.E., McClave S.A., Hoy N.W., et al. The Acute Physiology and Chronic Health Evaluation II classification system is a valid marker for physiologic stress in the critically ill patient. Crit Care Med 21 (1993) 363-367
20. Copson E.R., White H.E., Blaydes J.P., et al. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 6 (2006) 80. http://www.biomedcentral.com/1471-2407/6/80
21. Ottonello L., Cutolo M., Frumento G., et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) 41 (2002) 1249-1260
22. Ina K., Kusugami K., Hosokawa T., et al. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease. J Gastroenterol Hepatol 14 (1999) 46-53
23. Akahoshi T., Nagaoka T., Namai R., et al. Prevention of neutrophil apoptosis by monosodium urate crystals. Rheumatol Int 16 (1997) 231-235
24. Giamarellos-Bourboulis E.J., Routsi C., Plachouras D., et al. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?. Crit Care 10 (2006) R76. http://ccforum.com/content/10/3/R76
25. Goodman J.E., Hofseth L.J., Hussain S.P., et al. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 44 (2004) 3-9
26. Calvano S.E., Xiao W., Richards D.R., et al. A network-based analysis of systemic inflammation in humans. Nature 437 (2005) 1032-1037
27. Hudson J.D., Shoaibi M.A., Maestro R., et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190 (1999) 1375-1382
28. Mitchell R.A., Liao H., Chesney J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 99 (2002) 345-350
29. Hodge D.R., Peng B., Cherry J.C., et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65 (2005) 4673-4682
30. Diodato K.M., Schwacha M.G., Bland K.I., et al. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. MD. Cytokine 14 (2001) 162-169
31. van Eijk L.T., Dorresteijn M.J., Smits P., et al. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 35 (2007) 1464-1469
32. Coyle SM C.S., and Lowry S.F. Gender influences in vivo human responses to endotoxin. Shock 26 (2006) 538-543
33. Atwal G.S., Bond G.L., Metsuyanim S., et al. Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A 104 (2007) 4524-4529
34. Bond G.L., Hirshfield K.M., Kirchhoff T., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66 (2006) 5104-5110
35. Phelps M., Darley M., Primrose J.N., et al. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 63 (2003) 2616-2623
36. Qi J.S., Yuan Y., Desai-Yajnik V., et al. Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol Cell Biol 19 (1999) 864-872
37. Gou D.Y., Su W., Shao Y.C., et al. Euthyroid sick syndrome in trauma patients with severe inflammatory response syndrome. Chin J Traumatol 9 (2006) 115-117
38. Burchard E.G., Ziv E., Coyle N., et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348 (2003) 1170-1175